UNSPSC 51141535: Cabergoline

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C26H37N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LL60K9J05T, chemically known as ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)- but generally known as cabergoline, which bears US NIH Compound Identifier 54746. Cabergoline most often comes in base and diphosphate forms.

UNSPSC 51141535 Cabergoline is a Commodity code that in recent state and local procurement activity covers pharmaceutical procurement — specifically emergency-response medications and related systems. The code's recent solicitation record shows county health departments and emergency-services agencies buying naloxone (opioid-reversal medication) and drug deactivation systems to support community health and overdose-response initiatives. Issuing bodies under this code include county government procurement offices managing health-department budgets and emergency-preparedness contracts.

Seminole County, Florida posted an IFB on June 30, 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The contract carries a two-year initial term plus a one-year renewal option, requires vendors to meet E-Verify and drug-free workplace compliance, and includes workers' compensation, commercial general liability, and professional liability insurance requirements. The solicitation may be federally funded through FEMA, introducing additional compliance obligations under the Clean Air Act and Federal Water Pollution Control Act. Beyond this single recent opportunity, the source provides no additional state and local activity under the code across other jurisdictions or geographic regions.